Search results
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With...
Benzinga via Yahoo Finance· 12 months agoThe European Union has recommended for marketing authorization of AstraZeneca Plc's (NASDAQ: AZN)...
Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study
Zacks via Yahoo Finance· 2 years agoAmgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating...
Amgen Touts Positive Data From Soliris-Based Biosimilar For Rare Blood Disorder
Benzinga via Yahoo Finance· 2 years agoAmgen Inc (NASDAQ: AMGN) has announced topline results from the DAHLIA study crossover Phase 3 study...
Could This Biosimilar Drug Candidate Be a Winner for Amgen?
Motley Fool· 2 years agoThe pharmaceutical industry is fraught with risk and also filled with opportunity. On one hand, the...
FDA approves Amgen’s interchangeable biosimilar Bkemv
Pharmaceutical Technology via Yahoo Finance· 2 weeks agoThe US Food and Drug Administration (FDA) has approved Amgen's Bkemv (eculizumab-aeeb) as the first...
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
Zacks via Yahoo Finance· 2 months agoFDA approves AstraZeneca's (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for...
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Benzinga via Yahoo Finance· 2 weeks agoTuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first...
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
Reuters via Yahoo News· 2 weeks agoAmgen's drug will be marketed under the name Bkemv. Biosimilars are close copies of complex...
AstraZeneca's Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder
Benzinga via Yahoo Finance· 1 year agoAstraZeneca Plc (NASDAQ: AZN) released data from the Phase 3 ALPHA trial of danicopan as an add-on...
AstraZeneca's Blood Clot Treatment Hits Primary Goal In Rare Blood Disorder Trial
Benzinga via Yahoo Finance· 2 years agoAstraZeneca Plc (NASDAQ: AZN) said its Danicopan add-on anti-blood-clotting drug met a primary...